Search Results - "Throm, Stacy L"

Refine Results
  1. 1

    Pharmacokinetic Properties of Anticancer Agents for the Treatment of Central Nervous System Tumors: Update of the Literature by Jacus, Megan O., Daryani, Vinay M., Harstead, K. Elaine, Patel, Yogesh T., Throm, Stacy L., Stewart, Clinton F.

    Published in Clinical pharmacokinetics (01-03-2016)
    “…Despite significant improvement in outcomes for patients with hematologic malignancies and solid tumors over the past 10 years, patients with primary or…”
    Get full text
    Journal Article
  2. 2
  3. 3

    Low-level GATA2 overexpression promotes myeloid progenitor self-renewal and blocks lymphoid differentiation in mice by Nandakumar, Satish K, Johnson, Kyle, Throm, Stacy L, Pestina, Tamara I, Neale, Geoffrey, Persons, Derek A

    Published in Experimental hematology (01-07-2015)
    “…The transcription factor GATA2 is highly expressed in hematopoietic stem cells and is downregulated during lineage maturation. Gain of function mutations, loss…”
    Get full text
    Journal Article
  4. 4

    Population Pharmacokinetics of Bevacizumab in Children with Osteosarcoma: Implications for Dosing by TURNER, David C, NAVID, Fariba, HARSTEAD, K. Elaine, THROM, Stacy L, FREEMAN, Burgess B, STEWART, Clinton F, DAW, Najat C, SHENGHUA MAO, JIANRONG WU, SANTANA, Victor M, NEEL, Michael, RAO, Bhaskar, WILLERT, Jennifer Reikes, LOEB, David M

    Published in Clinical cancer research (15-05-2014)
    “…To describe sources of interindividual variability in bevacizumab disposition in pediatric patients and explore associations among bevacizumab pharmacokinetics…”
    Get full text
    Journal Article
  5. 5

    PU.1 regulates glutathione peroxidase expression in neutrophils by Throm, Stacy L., Klemsz, Michael J.

    Published in Journal of leukocyte biology (01-07-2003)
    “…Based on knockout models, the transcription factor PU.1 has been shown to be important for the maturation of neutrophils. As the list of genes PU.1 directly…”
    Get full text
    Journal Article
  6. 6
  7. 7

    Combination metronomic oral topotecan and pazopanib: a pharmacokinetic study in patients with gynecological cancer by Turner, David C, Tillmanns, Todd D, Harstead, K Elaine, Throm, Stacy L, Stewart, Clinton F

    Published in Anticancer research (01-09-2013)
    “…Combination metronomic topotecan plus pazopanib is active against preclinical models of gynecological cancer. Both agents are substrates for ATP-binding…”
    Get full text
    Journal Article
  8. 8
  9. 9
  10. 10

    MDM2 antagonist nutlin-3a reverses mitoxantrone resistance by inhibiting breast cancer resistance protein mediated drug transport by Zhang, Fan, Throm, Stacy L., Murley, Laura L., Miller, Laura A., Steven Zatechka, D., Kiplin Guy, R., Kennedy, Rachel, Stewart, Clinton F.

    Published in Biochemical pharmacology (01-07-2011)
    “…Nutlin-3a increases the intracellular accumulation of anti-cancer drugs (D) that are BCRP substrates and enhances cell death. Breast cancer resistance protein…”
    Get full text
    Journal Article
  11. 11

    Magnetic resonance imaging-guided microdialysis cannula implantation in a spontaneous high-grade glioma murine model by Elmeliegy, Mohamed A, Carcaboso, Angel M, L Chow, Lionel M, Zhang, Ziwei M, Calabrese, Christopher, Throm, Stacy L, Wang, Fan, Baker, Suzanne J, Stewart, Clinton F

    Published in Journal of pharmaceutical sciences (01-10-2011)
    “…Cerebral microdialysis is used to study anticancer drug penetration in the central nervous system (CNS) and brain tumors in animal models. Genetically…”
    Get more information
    Journal Article
  12. 12

    Observational Evaluations of Mice during Cerebral Microdialysis for Pediatric Brain Tumor Research by Jacus, Megan O, Rahija, Richard J., Davis, Abigail D, Throm, Stacy L, Stewart, Clinton F

    “…In vivo animal experiments are critical in the process of finding and developing new treatments for children with CNS tumors. Cerebral microdialysis, which…”
    Get full text
    Journal Article
  13. 13

    Pharmacokinetic Properties of Anticancer Agents for the Treatment of CNS Tumors: Update of the Literature by Jacus, Megan O., Daryani, Vinay M., Harstead, K. Elaine, Patel, Yogesh T., Throm, Stacy L., Stewart, Clinton F.

    Published in Clinical pharmacokinetics (01-03-2016)
    “…Despite significant improvement in outcomes for patients with hematological malignancies and solid tumors over the past 10 years, patients with primary or…”
    Get full text
    Journal Article
  14. 14

    Abstract 4526: Age dependent disposition of cyclophosphamide (CTX) and metabolites in infants ≤ 1 year old with brain tumors by Daryani, Vinay M., Owens, Thandranese S., Harstead, K. Elaine, Patel, Yogesh T., Turner, David C., Throm, Stacy L., Panetta, John C., Gajjar, Amar, Stewart, Clinton F.

    Published in Cancer research (Chicago, Ill.) (01-08-2015)
    “…Abstract An ongoing trial of risk-adapted therapy for infants and young children < 3 yrs old diagnosed with brain tumors includes IV CTX (NCT00602667). One aim…”
    Get full text
    Journal Article
  15. 15
  16. 16
  17. 17

    Abstract 4645: Clofarabine, a potent anticancer compound with limited penetration in an orthotopic murine model of ependymoma by Patel, Yogesh T., Jacus, Megan O., Davis, Abigail D., Vuppala, Pradeep, Dapper, Jason D., Freeman, Burgess B., Boulos, Nidal, Throm, Stacy L., Gilbertson, Richard J., Stewart, Clinton F.

    Published in Cancer research (Chicago, Ill.) (01-10-2014)
    “…Abstract Clofarabine, a deoxyadenosine analog, was a potent hit in our in vitro high-throughput screening against murine ependymoma neurospheres. To prioritize…”
    Get full text
    Journal Article
  18. 18
  19. 19
  20. 20

    Abstract 2742: Cerebral microdialysis for simultaneous sampling of crenolanib (PDGFR inhibitor) and erlotinib (EGFR inhibitor) in mouse models of glioma by Elmeliegy, Mohamed, Throm, Stacy L., Wang, Fan, Bai, Feng, Ramachandran, Abhijit, Stewart, Clinton F.

    Published in Cancer research (Chicago, Ill.) (15-04-2012)
    “…Abstract Cerebral microdialysis, a technique used to monitor anticancer drug disposition in the central nervous system (CNS), is commonly used to sample…”
    Get full text
    Journal Article